Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 406,704	$ 674,493
Accounts receivable, net	23,296	3,570
Marketable securities	27,483	10,435
Inventories	7,584	2,611
Prepaid expenses and other current assets	22,498	13,536
Amount due from related party	580	0
Total current assets	488,145	704,645
Property and equipment, net	2,944	3,300
Operating lease right-of-use asset	7,961	9,655
Other assets	20,961	7,427
Total assets	520,011	725,027
Current liabilities:
Accounts payable	12,250	17,809
Accrued expenses and other current liabilities	68,594	44,612
Share-based compensation liabilities	0	21,636
Deferred revenue	100,564	100,564
Amounts due to Pfizer	32,563	1,954
Cost share advance from Pfizer	33,818	92,415
Operating lease liability	2,148	1,807
Amounts due to related parties	393	543
Total current liabilities	250,330	281,340
Deferred revenue, non-current	375,706	397,369
Cost share advance from Pfizer, non-current	0	29,447
Long-term operating lease liability	7,041	9,189
Long-term debt, less current maturities (related party)	358,700	358,700
Other liabilities	1,711	2,947
Total liabilities	993,488	1,078,992
Commitments and contingencies (Note 14)
Shareholders’ deficit:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized; 94,858,446 and 91,000,869 issued and outstanding at March 31, 2022 and 2021, respectively	2	2
Additional paid-in capital	795,935	709,466
Accumulated other comprehensive loss	(17,285)	(17,285)
Accumulated deficit	(1,252,129)	(1,046,148)
Total shareholders’ deficit	(473,477)	(353,965)
Total liabilities and shareholders’ deficit	$ 520,011	$ 725,027